Azam Abbasi Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Azam Abbasi's research focuses on health economics and outcomes, particularly in the Iranian context. Abbasi has investigated the cost-effectiveness of various pharmaceutical interventions for cardiovascular conditions, including ticagrelor and clopidogrel for acute coronary syndrome, and apixaban and rivaroxaban for stroke prevention in non-valvular atrial fibrillation. Their work also includes estimating the direct medical costs associated with smoking-attributable non-communicable diseases. Additionally, Abbasi has contributed to research on quality of life assessments in patients with chronic conditions, such as multiple sclerosis. Their scholarly output includes 13 publications, with a notable collaborator at the University of Arkansas at Fayetteville, Young Min Kwon.
Metrics
- h-index: 5
- Publications: 13
- Citations: 197
Selected Publications
-
Genetic Factors of Campylobacter jejuni Required for Its Interactions with Free-Living Amoeba (2025)
Collaboration Network
Top Collaborators
- Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
- Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran
- Estimating the Direct Medical Costs of Smoking-Attributable Non-communicable Diseases in Northeastern Iran From 2015 to 2023
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
- Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran
- Estimating the Direct Medical Costs of Smoking-Attributable Non-communicable Diseases in Northeastern Iran From 2015 to 2023
- Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
- Cost-Effectiveness of Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in Iran
Similar Researchers
Based on overlapping research topics